Bionomics Limited today presented new important data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the European Society for Medical Oncology congress in Madrid, Spain. The data, presented by Dr Sumanta Pal, of the City of Hope Comprehensive Cancer Center in Duarte, CA, USA, emphasizes the plasma biomarker profile associated with favourable outcomes for patients treated with BNC105.
http://ift.tt/1nAEgKa
http://ift.tt/1nAEgKa
No comments:
Post a Comment